Stocks · News reference
Elanco Animal Health Announces Participation in Upcoming Investor Conferences
Elanco Animal Health management will participate in fireside chats at the 9th Annual Evercore Healthcare Conference and the Piper Sandler 38th Annual Healthcare Conference.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
J.P. Morgan Maintains Buy Rating and Raises Price Target for Elanco Animal Health
J.P. Morgan analyst Chris Schott has maintained a 'Buy' rating on Elanco Animal Health (ELAN) while increasing the price target from $33 to $35.
Elanco Animal Health: 3 Key Takeaways for Long-Term Investors
Elanco Animal Health reported Q3 2026 revenue growth of 11% year-over-year to $1.265 billion, driven by strong pricing power on proprietary products and innovation. The company reduced gross debt by $216 million, achieving sub-3.0x net leverage ahead of schedule, and is targeting $200-250 million in EBITDA savings through its Elanco Ascend efficiency program by 2030. Management maintains pricing discipline without aggressive discounting while expanding market share in high-value treatment categories.
Elanco Releases Consumer Research Affirming Resilience of Pet Health Spending
Elanco released findings from a national U.S. consumer survey indicating that pet owners continue to prioritize pet health spending despite macroeconomic pressures.
Elanco Animal Health Sees Strong Momentum Heading Into 2027
Elanco Animal Health beats Q3 earnings and revenue estimates, driven by Pet Health demand and pricing gains, while raising its full-year 2026 outlook.
Mexico Animal Healthcare Market Size and Share Analysis - Industry Trends and Growth Forecasts (2026-2031) | Diagnostics and Pet Care Fuel Growth to USD 3.34 Billion
Mexico's animal healthcare market is projected to grow from USD 2.13 billion in 2025 to USD 3.34 billion by 2031, with a CAGR of 7.84%. Growth is driven by rising companion animal spending, expanding livestock production, stronger biosecurity requirements, and innovation in veterinary diagnostics. Key challenges include high costs, limited rural infrastructure, and counterfeit medicines.